

Actis Generics Private Limited

April 17, 2025

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long Term Bank Facilities	40.00	CARE BB-; Stable; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category and Downgraded from CARE BB; Stable

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

CARE Ratings Ltd. had, vide its press release dated March 15, 2024, placed the rating(s) of Actis Generics Private Limited (AGPL) under the 'issuer non-cooperating' category as AGPL had failed to provide information for monitoring of the rating as agreed to in its Rating Agreement. AGPL continues to be non-cooperative despite repeated requests for submission of information through e-mails dated January 29, 2025, February 08, 2025, February 18, 2025 among others.

In line with the extant SEBI guidelines, CARE Ratings Ltd. has reviewed the rating on the basis of the best available information which however, in CARE Ratings Ltd.'s opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

The ratings assigned to the bank facilities of AGPL have been revised on account of non-availability of requisite information.

Analytical approach: Standalone

Outlook: Stable

Detailed description of the key rating drivers:

Please refer to PR dated March 15, 2024

Applicable criteria

CARE Rating's criteria on information adequacy risk and issuer non-cooperation
Policy on Default Recognition
Criteria on assigning outlook and credit watch

About the Company

Actis Generics Private Limited (AGPL) was incorporated in the year 2012 by Mr. B. Madhu Sudhana Reddy (Managing Director), Mr. B. Siva Kumar Reddy (Director) and Mr. P. Venkat Ram Reddy (Director). All the directors of the company are related and the operations commenced from January 2014. AGPL is involved in the manufacturing of bulk drugs, intermediates, Active Pharmaceutical Ingredients (API), Key starting materials (KSMs) and other speciality chemicals which are used as ingredients in manufacturing of human drugs and medicines. The company caters primarily to domestic market (90% of the revenue) to pharma players such as Bicon, MSN Laboratories, Lupin Limited, Intas etc. AGPL derives around 10% of the revenue from overseas markets primarily European countries such as Italy, Spain etc. and procures around 95% of raw materials indigenously and 5% by way of imports. The company has its registered office at Labbipet, Vijayawada and manufacturing unit at J.N. Pharma City, Paravada, Visakhapatnam, Andhra Pradesh.

Status of non-cooperation with previous CRA: CRISIL has continued the ratings assigned to the bank facilities of AGPL to the 'issuer not-cooperating' category vide press release dated May 09, 2024 on account of its inability to carryout review in the absence of requisite information from the company.

Any other information: Not Applicable

Rating History for last three years: Annexure-2

Covenants of rated instruments/facilities: Annexure-3

^{*}Issuer did not cooperate; based on best available information.

¹Complete definition of ratings assigned are available at www.careedge.in and other CARE Ratings Limited's publications.



Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD- MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook	
Fund-based - LT- Cash Credit		-	-	-	30.00	CARE BB-; Stable; ISSUER NOT COOPERATING*	
Fund-based - LT- Term Loan		-	-	30-09-2026	10.00	CARE BB-; Stable; ISSUER NOT COOPERATING*	

^{*}Issuer did not cooperate; based on best available information.

Annexure-2: Rating history for last three years

_	Aure 2. Ruting in		Current Ra	•	Rating History			
Sr. No	Name of the Instrument/Ban k Facilities	Typ e	Amount Outstandin g (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2025- 2026	Date(s) and Rating(s) assigned in 2024- 2025	Date(s) and Rating(s) assigned in 2023- 2024	Date(s) and Rating(s) assigned in 2022- 2023
1	Fund-based - LT- Term Loan	LT	10.00	CARE BB-; Stable; ISSUER NOT COOPERATING *	-	-	1)CARE BB; Stable; ISSUER NOT COOPERAT ING* (15-Mar- 24) 2)CARE BB+; Stable (05-Apr- 23)	-
2	Fund-based - LT- Cash Credit	LT	30.00	CARE BB-; Stable; ISSUER NOT COOPERATING *	-	-	1)CARE BB; Stable; ISSUER NOT COOPERAT ING* (15-Mar- 24) 2)CARE BB+; Stable (05-Apr- 23)	-

^{*}Issuer did not cooperate; based on best available information.

LT: Long term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not Applicable



Annexure-4: Complexity level of instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Cash Credit	Simple
2	Fund-based - LT-Term Loan	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please click here

Note on complexity levels of rated instruments: CARE Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.



Contact us

Media Contact

Mradul Mishra Director

CARE Ratings Limited Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

Relationship Contact

Ankur Sachdeva Senior Director

CARE Ratings Limited Phone: 912267543444

E-mail: Ankur.sachdeva@careedge.in

Analytical Contacts

Shachee Nakul Vyas Assistant Director **CARE Ratings Limited** Phone: 079-40265665

E-mail: shachee.tripathi@careedge.in

Jekin Shah Analyst

CARE Ratings Limited Phone: 079-40265679

E-mail: Jekin.Shah@careedge.in

Sakshi Thadani Associate Analyst CARE Ratings Limited

E-mail: Sakshi.Thadani@careedge.in

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.